Gilead Sciences recently announced its decision to withdraw Trodelvy from the market as a treatment for bladder cancer, following disappointing results from its confirmatory TROPiCS-04 clinical trial. This marks a notable shift for a drug that initially showed promise in shrinking tumors and
In a bold move that underscores its commitment to advancing cancer therapies, Novartis has taken a significant step by investing $70 million upfront in Chengdu Baiyu Pharmaceutical for global rights to a small molecule cancer treatment. This partnership is accompanied by potential milestone
In an ambitious endeavor to revolutionize cancer treatment, Boehringer Ingelheim and Circle Pharma have entered into a research partnership and license agreement aimed at developing a first-in-class cyclin inhibitor. This groundbreaking collaboration is set to provide novel treatment options for
The landscape of cancer treatment is ever-evolving, with new therapies continually pushing the boundaries of what is possible. Kiromic BioPharma's latest advancement, Deltacel, an allogeneic gamma delta T-cell (GDT) therapy, is showing significant promise in the treatment of advanced non-small cell
Boston-based Aktis Oncology is making significant strides in the biopharmaceutical industry, standing out for its innovative efforts in developing radiopharmaceutical medicines aimed at treating cancer. The company recently secured a substantial $175 million in a Series B funding round, designed to
The biotech and pharmaceutical industries are highly dynamic fields reliant on constant innovation, robust networking, and strategic investor relations. Professionals in these sectors must attend top biopharma conferences to keep pace with the latest advancements, regulatory trends, and emerging
